Request a FREE Sample of our FcRn Binding Kit!Request a FREE Sample of our FcRn Binding Kit!
Limited Edition Golden Llama is here! Check out how you can get one. Limited Edition Golden Llama is here! Check out how you can get one.
Request a FREE sample of our GMP products! Request a FREE sample of our GMP products!
5e5 of anti-IL-3 R alpha CAR-293 cells were stained with 100 μL of 1:25 dilution (4 μL stock solution in 100 μL FACS buffer) of APC-Labeled Human IL-3 R alpha Protein, His Tag (Cat. No. ILA-HA2H8) and negative control protein respectively. APC signal was used to evaluate the binding activity (QC tested).
5e5 of anti-IL-3 R alpha CAR-293 cells were stained with 100 μL of 1:25 dilution (4 μL stock solution in 100 μL FACS buffer) of PE-Labeled Human IL-3 R alpha, His Tag (Cat. No. ILA-HP2H8) and negative control protein respectively. PE signal was used to evaluate the binding activity (QC tested).
Anti-IL-3 R alpha Antibody, Human IgG1 immobilized on CM5 Chip can bind Human IL-3 R alpha, Fc Tag (Cat. No. ILA-H5252) with an affinity constant of 50.3 nM as determined in a SPR assay (Biacore T200) (QC tested).
Name | Research Code | Research Phase | Company | First Brand Name | First Approved Country | First Indication | First Approved Company | First Approved Date | Indications | Clinical Trials |
---|---|---|---|---|---|---|---|---|---|---|
Tagraxofusp | SL-401; DTIL-3; DT388 IL3 | Approved | Texas A&M University Development Foundation | Elzonris | United States | Blastic Plasmacytoid Dendritic Cell Neoplasm | Stemline Therapeutics Inc | 2018-12-21 | Leukemia; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Multiple Myeloma; Blastic Plasmacytoid Dendritic Cell Neoplasm; Primary Myelofibrosis; Leukemia, Myeloid, Acute; Lymphoma | Details |
Tagraxofusp | SL-401; DTIL-3; DT388 IL3 | Approved | Texas A&M University Development Foundation | Elzonris | United States | Blastic Plasmacytoid Dendritic Cell Neoplasm | Stemline Therapeutics Inc | 2018-12-21 | Leukemia; Myelodysplastic Syndromes; Leukemia, Myelomonocytic, Chronic; Multiple Myeloma; Blastic Plasmacytoid Dendritic Cell Neoplasm; Primary Myelofibrosis; Leukemia, Myeloid, Acute; Lymphoma | Details |
Name | Research Code | Research Phase | Company | Indications | Clinical Trials |
---|---|---|---|---|---|
CD123/CLL1 CAR-T Cell Therapy (Fujian Medical University) | Phase 3 Clinical | Fujian Medical University | Leukemia, Myeloid, Acute | Details | |
Flotetuzumab | S-80880; MGD-006; RES-234 | Phase 2 Clinical | Macrogenics Inc | Leukemia, Myelogenous, Chronic; Hematologic Neoplasms; Leukemia; Leukemia, Hairy Cell; Mastocytosis, Systemic; Hodgkin Disease; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Neoplasms, Plasma Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Leukemia, Myeloid, Acute; Leukemia, Biphenotypic, Acute | Details |
Talacotuzumab | CSL-362; JNJ-473; CSL-362-AML; JNJ-56022473; IL-13 MAb-CSL | Phase 2 Clinical | Csl Ltd | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
Vibecotamab | XmAb-14045 | Phase 2 Clinical | Xencor Inc | Leukemia, Myeloid; Myelodysplastic Syndromes; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details |
Pivekimab sunirine | IMGN-632 | Phase 2 Clinical | Immunogen Inc | Bone Marrow Neoplasms; Leukemia; Myeloproliferative Disorders; Myelodysplastic Syndromes; Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, Myeloid, Acute | Details |
CD123 CAR-T cell therapy(Chongqing Precision Biotechnology) | Phase 2 Clinical | Chongqing Precision Biotechnology Co Ltd | Leukemia; Leukemia, Myeloid; Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, Myeloid, Acute | Details | |
Anti-CD123 CAR T-cell therapy (Southwest Hospital) | Phase 2 Clinical | Southwest Hospital Chongqing | Leukemia, Myeloid | Details | |
AZD-9829 | AZD-9829; AZD9829 | Phase 2 Clinical | Astrazeneca Plc | Hematologic Diseases; Hematologic Neoplasms; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
Anti Tim-3/CD123 CAR-T Cell Therapy(Xuzhou Medical University) | Phase 2 Clinical | Xuzhou Medical University (Xzmu), The Affiliated Hospital Of Xuzhou Medical University | Leukemia, Myeloid, Acute | Details | |
MP0533 | MP0533 | Phase 2 Clinical | Molecular Partners Ag | Leukemia, Myeloid, Acute | Details |
APVO-436 | APVO-436; APVO436 | Phase 2 Clinical | Aptevo | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
SAR-443579 | SAR-443579; SAR443579; SAR579; IPH6101; IPH-6101 | Phase 2 Clinical | Sanofi | Hematologic Diseases; Myelodysplastic Syndromes; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Leukemia, Myeloid, Acute | Details |
Anti-CD123 CAR T-cell therapy (University of Pennsylvania/Novartis) | JEZ-567 | Phase 1 Clinical | Novartis Pharma Ag, University Of Pennsylvania | Leukemia, Myeloid, Acute | Details |
UCART-123 | UCART-123 | Phase 1 Clinical | Cellectis Sa | Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, Myeloid, Acute | Details |
JNJ-63709178 | JNJ-9178; CNTO-9958; JNJ-63709178 | Phase 1 Clinical | Johnson & Johnson Innovative Medicine, Genmab A/S | Leukemia, Myeloid, Acute | Details |
Anti-CD123 CAR T cell therapy (Shanghai GeneChem) | Phase 1 Clinical | Shanghai Genechem Co Ltd | Leukemia, Myeloid, Acute | Details | |
IM-23 (Beijing Immunochina Medical Science and Technology) | IM-23; IM-23 CAR-T | Phase 1 Clinical | Beijing Immunochina Medical Science & Technology Co Ltd | Leukemia, Myeloid, Acute | Details |
Anti-CD123 CAR T-cell therapy (Nanjing Legend Biotech) | Phase 1 Clinical | Leukemia, Myeloid, Acute | Details | ||
MB-102 (Mustang Bio) | MB-102 | Phase 1 Clinical | Mustang Bio Inc, City Of Hope National Medical Center | Neoplasm, Residual; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Leukemia, Biphenotypic, Acute | Details |
UniCAR-T-CD-123 | UniCAR-T-CD123; AVC-101 | Phase 1 Clinical | AvenCell Therapeutics Inc, AvenCell Europe GmbH | Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, Myeloid, Acute | Details |
Anti-CD123 CAR-T cell therapy (Wuhan Union Hospital) | Phase 1 Clinical | Wuhan BioRaid Biotechnology Co Ltd, Wuhan Union Hospital | Leukemia, Myeloid, Acute | Details | |
CD123 CAR-T cells (Hebei Senlang Biotechnology) | Phase 1 Clinical | Hebei Senlang Biological Technology Co Ltd | Leukemia, Myeloid, Acute | Details | |
ACLX-002 | ACLX-002 | Phase 1 Clinical | Arcellx Inc | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
MGD-024 | MGD-024 | Phase 1 Clinical | Macrogenics Inc | Leukemia, Myelogenous, Chronic; Leukemia, Hairy Cell; Hodgkin Disease; Myelodysplastic Syndromes; Neoplasms; Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, B-Cell; Leukemia, Myeloid, Acute | Details |
AFM-28 | AFM-28 | Phase 1 Clinical | Affimed | Leukemia, Promyelocytic, Acute; Neoplasms; Leukemia, Myeloid, Acute | Details |
VIP943 | BAY-943; VIP-943 | Phase 1 Clinical | Bayer AG | Myelodysplastic Syndromes; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details |
CD123 CAR-NK cell therapy(Beijing JD Biotech) | JD123; JD-123 | Phase 1 Clinical | Peking University People'S Hospital, Beijing JD Biotech Co Ltd | Leukemia, Myeloid, Acute | Details |
Universal CAR-T Cells therapy(Shenzhen Geno-Immune Medical Institute) | Phase 1 Clinical | Shenzhen Geno-Immune Medical Institute | Leukemia, Myeloid, Acute | Details | |
AVC-201 | AVC-201; Allo-RevCAR01-T-CD123 | Phase 1 Clinical | AvenCell Europe GmbH | Leukemia, Myeloid, Acute | Details |
CD123-CAR T cells(St Jude Children's Research Hospital) | Phase 1 Clinical | St Jude Children's Research Hospital | Myelodysplastic Syndromes; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Burkitt Lymphoma | Details | |
Allogenic CD123-CAR-NK Cells therapy(JD Biotech) | JD023 | Phase 1 Clinical | Beijing JD Biotech Co Ltd, Chinese Academy Of Military Medical Sciences | Leukemia, Myeloid, Acute | Details |
BYON-4413 | BYON-4413 | Phase 1 Clinical | Byondis Bv | Hematologic Neoplasms; Leukemia, Myeloid, Acute | Details |
GR-1901 | GR1901; GR-1901 | Phase 1 Clinical | Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd, Genrix (Shanghai) Biopharmaceutical Co Ltd | Leukemia, Myeloid, Acute | Details |
SQZ-622(Novartis Pharma) | SQZ-622 | Phase 1 Clinical | Novartis Pharma Ag | Leukemia, Myeloid, Acute | Details |
UniCAR02-T | UniCAR02-T | Phase 1 Clinical | Cellex Patient Treatment Gmbh | Kidney Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
IL3 CAR T-cell therapy (Yake Biotechnology) | Phase 1 Clinical | Zhejiang University | Leukemia, Myeloid, Acute | Details | |
CD123/CLL1 CAR-T Cell Therapy (Fujian Medical University) | Phase 3 Clinical | Fujian Medical University | Leukemia, Myeloid, Acute | Details | |
Flotetuzumab | S-80880; MGD-006; RES-234 | Phase 2 Clinical | Macrogenics Inc | Leukemia, Myelogenous, Chronic; Hematologic Neoplasms; Leukemia; Leukemia, Hairy Cell; Mastocytosis, Systemic; Hodgkin Disease; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor T-Cell Lymphoblastic Leukemia-Lymphoma; Neoplasms, Plasma Cell; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Leukemia, Myeloid, Acute; Leukemia, Biphenotypic, Acute | Details |
Talacotuzumab | CSL-362; JNJ-473; CSL-362-AML; JNJ-56022473; IL-13 MAb-CSL | Phase 2 Clinical | Csl Ltd | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
Vibecotamab | XmAb-14045 | Phase 2 Clinical | Xencor Inc | Leukemia, Myeloid; Myelodysplastic Syndromes; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details |
Pivekimab sunirine | IMGN-632 | Phase 2 Clinical | Immunogen Inc | Bone Marrow Neoplasms; Leukemia; Myeloproliferative Disorders; Myelodysplastic Syndromes; Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, Myeloid, Acute | Details |
CD123 CAR-T cell therapy(Chongqing Precision Biotechnology) | Phase 2 Clinical | Chongqing Precision Biotechnology Co Ltd | Leukemia; Leukemia, Myeloid; Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, Myeloid, Acute | Details | |
Anti-CD123 CAR T-cell therapy (Southwest Hospital) | Phase 2 Clinical | Southwest Hospital Chongqing | Leukemia, Myeloid | Details | |
AZD-9829 | AZD-9829; AZD9829 | Phase 2 Clinical | Astrazeneca Plc | Hematologic Diseases; Hematologic Neoplasms; Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
Anti Tim-3/CD123 CAR-T Cell Therapy(Xuzhou Medical University) | Phase 2 Clinical | Xuzhou Medical University (Xzmu), The Affiliated Hospital Of Xuzhou Medical University | Leukemia, Myeloid, Acute | Details | |
MP0533 | MP0533 | Phase 2 Clinical | Molecular Partners Ag | Leukemia, Myeloid, Acute | Details |
APVO-436 | APVO-436; APVO436 | Phase 2 Clinical | Aptevo | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
SAR-443579 | SAR-443579; SAR443579; SAR579; IPH6101; IPH-6101 | Phase 2 Clinical | Sanofi | Hematologic Diseases; Myelodysplastic Syndromes; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, B-Cell; Leukemia, Myeloid, Acute | Details |
Anti-CD123 CAR T-cell therapy (University of Pennsylvania/Novartis) | JEZ-567 | Phase 1 Clinical | Novartis Pharma Ag, University Of Pennsylvania | Leukemia, Myeloid, Acute | Details |
UCART-123 | UCART-123 | Phase 1 Clinical | Cellectis Sa | Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, Myeloid, Acute | Details |
JNJ-63709178 | JNJ-9178; CNTO-9958; JNJ-63709178 | Phase 1 Clinical | Johnson & Johnson Innovative Medicine, Genmab A/S | Leukemia, Myeloid, Acute | Details |
Anti-CD123 CAR T cell therapy (Shanghai GeneChem) | Phase 1 Clinical | Shanghai Genechem Co Ltd | Leukemia, Myeloid, Acute | Details | |
IM-23 (Beijing Immunochina Medical Science and Technology) | IM-23; IM-23 CAR-T | Phase 1 Clinical | Beijing Immunochina Medical Science & Technology Co Ltd | Leukemia, Myeloid, Acute | Details |
Anti-CD123 CAR T-cell therapy (Nanjing Legend Biotech) | Phase 1 Clinical | Leukemia, Myeloid, Acute | Details | ||
MB-102 (Mustang Bio) | MB-102 | Phase 1 Clinical | Mustang Bio Inc, City Of Hope National Medical Center | Neoplasm, Residual; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute; Leukemia, Biphenotypic, Acute | Details |
UniCAR-T-CD-123 | UniCAR-T-CD123; AVC-101 | Phase 1 Clinical | AvenCell Therapeutics Inc, AvenCell Europe GmbH | Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, Myeloid, Acute | Details |
Anti-CD123 CAR-T cell therapy (Wuhan Union Hospital) | Phase 1 Clinical | Wuhan BioRaid Biotechnology Co Ltd, Wuhan Union Hospital | Leukemia, Myeloid, Acute | Details | |
CD123 CAR-T cells (Hebei Senlang Biotechnology) | Phase 1 Clinical | Hebei Senlang Biological Technology Co Ltd | Leukemia, Myeloid, Acute | Details | |
ACLX-002 | ACLX-002 | Phase 1 Clinical | Arcellx Inc | Myelodysplastic Syndromes; Leukemia, Myeloid, Acute | Details |
MGD-024 | MGD-024 | Phase 1 Clinical | Macrogenics Inc | Leukemia, Myelogenous, Chronic; Leukemia, Hairy Cell; Hodgkin Disease; Myelodysplastic Syndromes; Neoplasms; Blastic Plasmacytoid Dendritic Cell Neoplasm; Leukemia, B-Cell; Leukemia, Myeloid, Acute | Details |
AFM-28 | AFM-28 | Phase 1 Clinical | Affimed | Leukemia, Promyelocytic, Acute; Neoplasms; Leukemia, Myeloid, Acute | Details |
VIP943 | BAY-943; VIP-943 | Phase 1 Clinical | Bayer AG | Myelodysplastic Syndromes; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Leukemia, Myeloid, Acute | Details |
CD123 CAR-NK cell therapy(Beijing JD Biotech) | JD123; JD-123 | Phase 1 Clinical | Peking University People'S Hospital, Beijing JD Biotech Co Ltd | Leukemia, Myeloid, Acute | Details |
Universal CAR-T Cells therapy(Shenzhen Geno-Immune Medical Institute) | Phase 1 Clinical | Shenzhen Geno-Immune Medical Institute | Leukemia, Myeloid, Acute | Details | |
AVC-201 | AVC-201; Allo-RevCAR01-T-CD123 | Phase 1 Clinical | AvenCell Europe GmbH | Leukemia, Myeloid, Acute | Details |
CD123-CAR T cells(St Jude Children's Research Hospital) | Phase 1 Clinical | St Jude Children's Research Hospital | Myelodysplastic Syndromes; Blastic Plasmacytoid Dendritic Cell Neoplasm; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Precursor B-Cell Lymphoblastic Leukemia-Lymphoma; Burkitt Lymphoma | Details | |
Allogenic CD123-CAR-NK Cells therapy(JD Biotech) | JD023 | Phase 1 Clinical | Beijing JD Biotech Co Ltd, Chinese Academy Of Military Medical Sciences | Leukemia, Myeloid, Acute | Details |
BYON-4413 | BYON-4413 | Phase 1 Clinical | Byondis Bv | Hematologic Neoplasms; Leukemia, Myeloid, Acute | Details |
GR-1901 | GR1901; GR-1901 | Phase 1 Clinical | Chongqing Zhixiang Jintai Biopharmaceutical Co Ltd, Genrix (Shanghai) Biopharmaceutical Co Ltd | Leukemia, Myeloid, Acute | Details |
SQZ-622(Novartis Pharma) | SQZ-622 | Phase 1 Clinical | Novartis Pharma Ag | Leukemia, Myeloid, Acute | Details |
UniCAR02-T | UniCAR02-T | Phase 1 Clinical | Cellex Patient Treatment Gmbh | Kidney Neoplasms; Prostatic Neoplasms; Breast Neoplasms; Colorectal Neoplasms; Carcinoma, Non-Small-Cell Lung | Details |
IL3 CAR T-cell therapy (Yake Biotechnology) | Phase 1 Clinical | Zhejiang University | Leukemia, Myeloid, Acute | Details |
This web search service is supported by Google Inc.